The Urology business is facing flat growth due to underperformance in its stone franchise from China's volume-based procurement policies and 'commercial disruption' in its sacral neuromodulation franchise. This creates a need for tools to improve sales forecasting, manage complex pricing environments, and resolve commercial execution issues.
Filing excerpt
In the second quarter and first six months of 2026, reported net sales growth was relatively flat, primarily driven by underperformance in our stone franchise as a result of volume-based-procurement in China, and commercial disruption in our sacral neuromodulation franchise.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10qbookingsDeclineGet every 10-Q signal for Boston Scientific and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Boston Scientific this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/e9fa6273-cda1-4aef-a11c-69a5dcdabf76 returns this record as JSON. POST /v1/companies/enrich returns every signal for bostonscientific.com.
{
"signal_id": "e9fa6273-cda1-4aef-a11c-69a5dcdabf76",
"signal_type": "sec-10q",
"signal_subtype": "bookingsDecline",
"detected_at": "2026-08-04T07:04:54.601+00:00",
"company": {
"name": "Boston Scientific",
"domain": "bostonscientific.com"
},
"data": {
"detail": "The Urology business is facing flat growth due to underperformance in its stone franchise from China's volume-based procurement policies and 'commercial disruption' in its sacral neuromodulation franchise. This creates a need for tools to improve sales forecasting, manage complex pricing environments, and resolve commercial execution issues.",
"metrics": {
"pct": 0.011,
"timeframe": "current_quarter",
"pct_context": "Urology reported net sales growth for Q2 2026."
},
"summary": "Urology business underperforms due to China VBP and 'commercial disruption'.",
"excerpts": "In the second quarter and first six months of 2026, reported net sales growth was relatively flat, primarily driven by underperformance in our stone franchise as a result of volume-based-procurement in China, and commercial disruption in our sacral neuromodulation franchise.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm",
"filing_date": "2026-08-03",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Sales effectiveness tools",
"signal_category": "revenue",
"regions_mentioned": [
"China"
]
}
}
curl https://signals.autobound.ai/v1/signals/e9fa6273-cda1-4aef-a11c-69a5dcdabf76 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.